LeMaitre Vascular (LMAT)
(Delayed Data from NSDQ)
$89.04 USD
-0.82 (-0.91%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $89.05 +0.01 (0.01%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$89.04 USD
-0.82 (-0.91%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $89.05 +0.01 (0.01%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth F Momentum D VGM
Zacks News
Here's Why Investors Should Hold Humana (HUM) in Portfolio
by Zacks Equity Research
Humana (HUM) remains well-poised for growth on the back of an expanding Medicare Advantage membership, upgraded health plan offering suite and solid cash reserves.
Cigna (CI) Eases Care Delivery With Prior Authorization Removal
by Zacks Equity Research
Cigna's (CI) branch, Cigna Healthcare, lifts the prior authorization requirement on 600-plus medical services, thereby easing administrative burdens and making way for simplified care delivery.
Molina Healthcare (MOH) Wins Medicaid Deal From New Mexico HSD
by Zacks Equity Research
Molina Healthcare (MOH) receives a contract from the New Mexico HSD, subsequent to which it can effectively serve the statewide Medicaid members.
LeMaitre Vascular (LMAT) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of 15.63% and 3.78%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
ABT vs. LMAT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ABT vs. LMAT: Which Stock Is the Better Value Option?
Strength Seen in Zimmer (ZBH): Can Its 3.8% Jump Turn into More Strength?
by Zacks Equity Research
Zimmer (ZBH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
LeMaitre (LMAT) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
LeMaitre (LMAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Momentum Stocks to Buy for May 23rd
by Zacks Equity Research
ONON, PKOH and LMAT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 23, 2023.
What Makes LeMaitre Vascular (LMAT) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does LeMaitre Vascular (LMAT) have what it takes to be a top stock pick for momentum investors? Let's find out.
LeMaitre Vascular (LMAT) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of 8% and 7.63%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ZBH or LMAT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ZBH vs. LMAT: Which Stock Is the Better Value Option?
ZBH vs. LMAT: Which Stock Is the Better Value Option?
by Zacks Equity Research
ZBH vs. LMAT: Which Stock Is the Better Value Option?
LeMaitre Vascular (LMAT) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of -3.85% and 0.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ZBH vs. LMAT: Which Stock Is the Better Value Option?
by Zacks Equity Research
ZBH vs. LMAT: Which Stock Is the Better Value Option?
Aurora Cannabis Inc. (ACB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of -100% and 19.61%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
VREX vs. LMAT: Which Stock Is the Better Value Option?
by Zacks Equity Research
VREX vs. LMAT: Which Stock Is the Better Value Option?
ESLOY vs. LMAT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ESLOY vs. LMAT: Which Stock Is the Better Value Option?
ESLOY or LMAT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ESLOY vs. LMAT: Which Stock Is the Better Value Option?
ESLOY vs. LMAT: Which Stock Is the Better Value Option?
by Zacks Equity Research
ESLOY vs. LMAT: Which Stock Is the Better Value Option?
LeMaitre Vascular (LMAT) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of -10.71% and 2.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Stryker (SYK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: LeMaitre Vascular (LMAT) Q3 Earnings Expected to Decline
by Zacks Equity Research
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abbott (ABT) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 26.37% and 8.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ZBH vs. LMAT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ZBH vs. LMAT: Which Stock Is the Better Value Option?
LeMaitre Vascular (LMAT) Lags Q2 Earnings Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of -9.38% and 2.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?